| Methods | Randomised cross‐over trial. Duration: each treatment arm lasted 5 consecutive days with 1 week washout period in between. Multicentre: 7 centres in Spain. |
| Participants | 19 CF stable participants, mean age (SD) 24.2 yrs (7.6) and FEV₁ 70.8% predicted (24.3). |
| Interventions | Intervention A: combined therapy (nebulised hypertonic saline plus oscillatory PEP (Acapella®)). Intervention B: classic nebulised hypertonic saline. |
| Outcomes | Sputum volume (during nebulisation, the subsequent physiotherapy and 24 h post‐physiotherapy). Pulmonary function, Leicester Cough Questionnaire (LCQ) and Cough and Sputum Assessment Questionnaire (CASA‐Q) (evaluated before and after each intervention). Participant preference (assessed using a Likert test (range 6–30). |
| Notes |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.